Clinical and pharmacogenetic risk factors for the development of early adverse reactions when prescribing antipsychotics for the treatment of conduct disorders in boys without intellectual disability

Objectives To identify associations between the DRD2 rs1800497 and HTR2A rs6311/rs6313 genotypes, adjunctive pharmacotherapy and the effectiveness and safety of antipsychotics prescribed for conduct disorders in boys without intellectual disability in first 14 days of treatment. Methods This study included 115 boys aged 7–12 years without intellectual disability hospitalized for conduct disorders and prescribed an antipsychotic. Follow-up lasted 14 days, with examinations at enrollment, day 5 and 14. Effectiveness was assessed with the CGI-S, CGI-I and CGAS scales; safety, using the UKU SERS and SAS scales. All patients were genotyped for DRD2 rs1800497, HTR2A rs6311 and rs6313. A Poisson regression analysis was carried out to identify the most significant risk factors for the development of adverse drug reactions. Results No polymorphism was significantly associated with effectiveness. Physical aggression towards peers before hospitalization was more frequent in DRD2 CT+TT carriers (95.12% vs 64.38%; p=0.0002). No other factors were identified that were significantly associated with the effectiveness of treatment for conduct disorders. Regression analysis revealed that the frequency of complaints about ADRs was predominantly associated with the prescription of mood stabilisers. In particular, the prescription of a mood stabiliser was associated with a higher frequency of complaints regarding ‘Disturbances of the autonomic nervous system’ (ß=3.116; SE = 0.89; p<0.001) and the total number of ADRs (ß =1.001; SE = 0.42; p=0.018). On day 14, the prescription of mood stabilisers was associated with a higher frequency of ‘Mental disturbances’ (ß =2.026; SE = 0.87; p=0.019), ‘disturbances of the autonomic nervous system’ (ß =3.183; SE = 0.89; p<0.001) and the total number of ADRs (ß =2.4; SE = 0.5; p<0.001). Conclusion Adjunctive pharmacotherapy was the strongest risk factor of early adverse reactions to antipsychotics. Pharmacogenetic factors ( DRD2 rs1800497, HTR2A rs6311, rs6313) showed a weak association with the risk of developing adverse reactions; there is a high likelihood of a false-positive result. Further research into pharmacogenetic predictors of antipsychotic safety in children with conduct disorders and without intellectual disability is needed.

Authors

Institutions

Publication Details

Journal
Frontiers in Psychiatry
Published
2026-11-19
DOI
https://doi.org/10.3389/fpsyt.2026.1984335
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical and pharmacogenetic risk factors for the development of early adverse reactions when prescribing antipsychotics for the treatment of conduct disorders in boys without intellectual disability

Тучкова Светлана Николаевна, Karin Badavievich Mirzaev, Farid Rafaelevich Aisin, P. V. Shimanov et al.
Frontiers in Psychiatry
Schizophrenia research and treatment
article

Clinical and pharmacogenetic risk factors for the development of early adverse reactions when prescribing antipsychotics for the treatment of conduct disorders in boys without intellectual disability

Тучкова Светлана Николаевна, Karin Badavievich Mirzaev, Farid Rafaelevich Aisin, P. V. Shimanov, Yuriy S. Shevchenko, Dmitriy V. Ivashchenko, Mariia Ivashchenko, Rimma V. Kondratieva, Ivan N. Korsakov, Mikhail D. Che, Dmitry A. Sychev, Ekaterina A. Zevaikina
article en

Abstract

Objectives To identify associations between the DRD2 rs1800497 and HTR2A rs6311/rs6313 genotypes, adjunctive pharmacotherapy and the effectiveness and safety of antipsychotics prescribed for conduct disorders in boys without intellectual disability in first 14 days of treatment. Methods This study included 115 boys aged 7–12 years without intellectual disability hospitalized for conduct disorders and prescribed an antipsychotic. Follow-up lasted 14 days, with examinations at enrollment, day 5 and 14. Effectiveness was assessed with the CGI-S, CGI-I and CGAS scales; safety, using the UKU SERS and SAS scales. All patients were genotyped for DRD2 rs1800497, HTR2A rs6311 and rs6313. A Poisson regression analysis was carried out to identify the most significant risk factors for the development of adverse drug reactions. Results No polymorphism was significantly associated with effectiveness. Physical aggression towards peers before hospitalization was more frequent in DRD2 CT+TT carriers (95.12% vs 64.38%; p=0.0002). No other factors were identified that were significantly associated with the effectiveness of treatment for conduct disorders. Regression analysis revealed that the frequency of complaints about ADRs was predominantly associated with the prescription of mood stabilisers. In particular, the prescription of a mood stabiliser was associated with a higher frequency of complaints regarding ‘Disturbances of the autonomic nervous system’ (ß=3.116; SE = 0.89; p<0.001) and the total number of ADRs (ß =1.001; SE = 0.42; p=0.018). On day 14, the prescription of mood stabilisers was associated with a higher frequency of ‘Mental disturbances’ (ß =2.026; SE = 0.87; p=0.019), ‘disturbances of the autonomic nervous system’ (ß =3.183; SE = 0.89; p<0.001) and the total number of ADRs (ß =2.4; SE = 0.5; p<0.001). Conclusion Adjunctive pharmacotherapy was the strongest risk factor of early adverse reactions to antipsychotics. Pharmacogenetic factors ( DRD2 rs1800497, HTR2A rs6311, rs6313) showed a weak association with the risk of developing adverse reactions; there is a high likelihood of a false-positive result. Further research into pharmacogenetic predictors of antipsychotic safety in children with conduct disorders and without intellectual disability is needed.

Frontiers in PsychiatryVol. 17
Lomonosov Moscow State University (RU), Pirogov Russian National Research Medical University (RU), Russian Medical Academy of Continuous Professional Education (RU), Ministry of Health of the Russian Federation (RU), Scientific Center of Children's Health (RU), Russian Scientific Center of Surgery (RU)
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon